A Study Evaluating the Efficacy and Safety of Risvutatug Rezetecan in Participants With Advanced Sarcomas (EMBOLD Sarcoma-202)

The main goal of this study is to test a new medicine, Risvutatug Rezetecan also called Ris-Rez. We want to see if this medicine can help people with certain types of cancer, whether its safe to use, how well people tolerate it, and how their bodies handle the drug (how its absorbed and broken down). This research is for adolescents and adults who have either: Osteosarcoma, which is a type of bone cancer, or Soft Tissue Sarcoma, which is a type of cancer that starts in soft body tissues (like muscle, fat, or nerves). In both cancer types the cancer must have already been treated, but has come

Trial Details

NCT ID

NCT07602777

Phase

PHASE1 / PHASE2

Sponsor

GlaxoSmithKline

Status

RECRUITING

Cancer Type

Osteosarcoma Sarcoma

Interventions

Ris-Rez
G-CSF

Locations (sample)

Toronto, Ontario, Canada|43.70643,-79.39864
Montreal, Quebec, Canada|45.50884,-73.58781
Bordeaux, France|44.84124,-0.58046
Lyon, France|45.74906,4.84789
Villejuif, France|48.7939,2.35992

Key Eligibility Criteria

\- Participants are eligible to be included in the study only if all of the following criteria apply
Participants must be ≥ 12 years of age.
Has histologically confirmed unresectable advanced or metastatic R/R OSA (Cohort 1) or unresectable advanced or metastatic STS (Cohort 2) that has …
Has documented disease progression on the last line of systemic treatment as confirmed by radiological imaging

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Osteosarcoma Sarcoma Trials on Trialify →